{"disease":{"id":"chronic-pain","name":"Chronic pain","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":8,"pipeline_drug_count":0,"trial_count":33},"drugs":{"marketed":[{"drug_id":"buprenorphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"hydromorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"duloxetine","indication_name":"Chronic Musculoskeletal Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cymbalta","generic_name":"duloxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake","drug_class":"Serotonin and norepinephrine reuptake inhibitor (SNRI)","quality_score":68,"revenue":null,"mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms."},{"drug_id":"fentanyl-f2","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of chronic pain associated with adult patients with multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"oxycodone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fentanyl","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"morphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"morphine","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"diflunisal","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dolobid","generic_name":"DIFLUNISAL","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"neurontin","indication_name":"Chronic low back pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"morphine-sulfate","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"morphine-sulfate","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"oxymorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"ziconotide-acetate","indication_name":"Severe Chronic Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ZICONOTIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":32,"revenue":null,"mechanism":null},{"drug_id":"oxycontin","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"chembl-chembl2103744","indication_name":"Chronic Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MORPHINE SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"danuglipron","indication_name":"Treatment of acute and chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Danuglipron","generic_name":"danuglipron","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":49,"revenue":null,"mechanism":"Danuglipron is a small-molecule GLP-1 receptor agonist."},{"drug_id":"tramadol","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultram","generic_name":"tramadol","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"","quality_score":40,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":26,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04053335","title":"Smarter Care Virginia, Examining Low-Value Care in Virginia","phase":"","overall_status":"COMPLETED","enrollment_count":5000000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05443503","title":"Stanford Spine Keeper - Managing Your Low Back Pain","phase":"NA","overall_status":"SUSPENDED","enrollment_count":500000,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT04839848","title":"Chronic Postoperative Pain After the Lichtenstein Groin Hernioplasty","phase":"","overall_status":"COMPLETED","enrollment_count":80733,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06070766","title":"RIVER At Home Ketamine Protocols","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"RIVER Foundation","has_results":false},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT04878562","title":"I-COPE Study: Opioid Use and Pain Management in Older Adults","phase":"NA","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT04657159","title":"Health-economic Evaluation of Interventional Pain Management Compared to Pain Rehabilitation","phase":"","overall_status":"COMPLETED","enrollment_count":15611,"lead_sponsor_name":"Eques Indolor AB","has_results":false},{"nct_id":"NCT04838028","title":"Chronic Postoperative Pain After Laparoendoscopic Groin Hernia Repair","phase":"","overall_status":"COMPLETED","enrollment_count":15360,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04426812","title":"Measuring Chronic Pain Impact: Measurement Enhancement for Chronic Pain","phase":"","overall_status":"COMPLETED","enrollment_count":11146,"lead_sponsor_name":"RAND","has_results":false},{"nct_id":"NCT03421223","title":"Digital Signals in Chronic Pain (DiSCover Project)","phase":"","overall_status":"COMPLETED","enrollment_count":10161,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT05877157","title":"Pain AND Opioids After Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University of Aberdeen","has_results":false},{"nct_id":"NCT05811663","title":"Health Care Use and Costs of Functional Somatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":9656,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT04256720","title":"The Multi-Ethnic Lifestyle Study","phase":"","overall_status":"UNKNOWN","enrollment_count":9500,"lead_sponsor_name":"University of Leicester","has_results":false},{"nct_id":"NCT03264521","title":"Patient Engagement Via Crowdsourcing","phase":"","overall_status":"COMPLETED","enrollment_count":8193,"lead_sponsor_name":"RAND","has_results":false},{"nct_id":"NCT06008496","title":"Patient Reported Outcomes, Postoperative Pain and Pain Relief After Day Case Surgery (POPPY)","phase":"","overall_status":"COMPLETED","enrollment_count":7839,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT05372406","title":"Clinical Prediction Model and External Validation of Chronic Postsurgical Pain in Elders","phase":"","overall_status":"COMPLETED","enrollment_count":7770,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06835868","title":"Neuro-Pain Provides a Dynamic and Interactive Register for the Invasvive Neuromodulatory Therapies for Different Chronic Pain Syndromes. Patients Living in Belgium and Suffering From Persistent Spinal Pain Syndromes Type 2 as Well as Suffering From Complex Regional Pain Syndromes Are Included.","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT04864223","title":"Classifying and Predicting Long-term Pain and Function in Older Adults","phase":"","overall_status":"COMPLETED","enrollment_count":6783,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04880096","title":"Cohort of Chronic Pain Patients","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT05326737","title":"Evaluation of Pain Trajectories After Surgery and Their Potential Relationship With Chronicity at 3 Months","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT03768011","title":"Subjective Observational Study of Patients Using Transdermal Cream Medication And/Or Transdermal Patches With Or Without Oral Non-Narcotic Medications","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Data Collection Analysis Business Management","has_results":false},{"nct_id":"NCT03626389","title":"Clinical Course of Patients Receiving Physiotherapy Services in Primary Health Care","phase":"","overall_status":"COMPLETED","enrollment_count":4985,"lead_sponsor_name":"University of Oslo","has_results":false},{"nct_id":"NCT04445792","title":"A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)","phase":"NA","overall_status":"COMPLETED","enrollment_count":4284,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT05920200","title":"Factors Influencing the Results of Treatment in Patients With Hernias of Various Localizations","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Immanuel Kant Baltic Federal University","has_results":false},{"nct_id":"NCT05097521","title":"Assessing Pain, Patient Reported Outcomes and Complementary and Integrative Health","phase":"","overall_status":"COMPLETED","enrollment_count":3726,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05687929","title":"Real-World Registry Study on Clinical Analgesic Effect of Acetylaconitine Tablets","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Ke Ma","has_results":false},{"nct_id":"NCT04490798","title":"Effectiveness of Acupuncture Clinical Pathway","phase":"","overall_status":"COMPLETED","enrollment_count":3245,"lead_sponsor_name":"Hospital Son Llatzer","has_results":false},{"nct_id":"NCT06545513","title":"Depression and Anxiety Among Chronic Pain Patients in the Netherlands","phase":"","overall_status":"COMPLETED","enrollment_count":3240,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT07200362","title":"Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Pain in Musculoskeletal System","phase":"","overall_status":"COMPLETED","enrollment_count":3029,"lead_sponsor_name":"Jiangsu Kanion Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT02528188","title":"Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3021,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT04142177","title":"Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response","phase":"NA","overall_status":"RECRUITING","enrollment_count":2529,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06228300","title":"Registro Italiano Dei Pazienti Affetti da Dolore Cronico","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Societa Italiana Anestesia Analgesia Rianimazione e Terapia Intensiva","has_results":false},{"nct_id":"NCT06382077","title":"Chronic Post Surgical Pain-Cardiac","phase":"","overall_status":"COMPLETED","enrollment_count":2442,"lead_sponsor_name":"Ondokuz Mayıs University","has_results":false},{"nct_id":"NCT06353100","title":"Chronic Pain in the General Population of Chile","phase":"","overall_status":"COMPLETED","enrollment_count":2365,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT04523714","title":"Tailored Non-Pharmacotherapy Services for Chronic Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":2333,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT05661760","title":"Predicting Successful Outcome of Interdisciplinary Biopsychosocial Rehabilitation in Osteoarthritis","phase":"","overall_status":"UNKNOWN","enrollment_count":2309,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT05478642","title":"Influence of Psychological Status on the Results of Pain Treatment in Patients With Gunshot and Mine-explosive Wounds","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT05485298","title":"The Influence of the Volume of Injuries and Surgical Operations on the Results of Pain Treatment in Patients With Gunshot and Mine-explosive Wounds at the Stages of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT05485116","title":"The Influence of Therapeutic Tactics of Analgesia on the Long-term Results of Pain Treatment in Patients With Gunshot and Mine-explosive Wounds","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT05485337","title":"Effectiveness of Therapeutic Tactics of Analgesia in Patients With Gunshot and Mine-explosive Wounds at the Stages of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT05482061","title":"Predictors of Treatment Failure Pain Among Patients Gunshot Wounds","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT05478668","title":"Predictors of Pain Chronicity in Patients With Gunshot and Mine-explosive Wounds","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT05485311","title":"The Influence of the Results of Surgical Treatment in Patients With Gunshot and Mine-explosive Wounds on the Formation of Chronic Pain","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT05485324","title":"The Concept of Pain Treatment in Patients With Gunshot and Mine-explosive Wounds and to Develop an Algorithm for Analgesia at the Stages of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":2215,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT03162952","title":"RAND Center of Excellence for the Study of Appropriateness of Care in CAM","phase":"","overall_status":"COMPLETED","enrollment_count":2025,"lead_sponsor_name":"RAND","has_results":false},{"nct_id":"NCT03296007","title":"Evaluating the Psychophysiological Effects of a Smartphone-Based Mindfulness Task","phase":"NA","overall_status":"COMPLETED","enrollment_count":2016,"lead_sponsor_name":"York University","has_results":false},{"nct_id":"NCT04726254","title":"The JULI Registry--Hemp and Cannabis Observational Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Juva Life","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}